- SynonymEGFRvIII
- SourceBiotinylated Human EGFRvIII, Avitag,His Tag (EGR-H82E0) is expressed from human 293 cells (HEK293). It contains AA Leu 25 - Ser 378 (Accession # NP_001333870.1).Predicted N-terminus: Leu 25Request for sequence
- Molecular Characterization
This protein carries an Avi tag (Avitag™) at the C-terminus, followed by a polyhistidine tag.
The protein has a calculated MW of 42.2 kDa. The protein migrates as 60-90 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
- BiotinylationBiotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
- Biotin:Protein RatioThe biotin to protein ratio is 0.5-1 as determined by the HABA assay.
- EndotoxinLess than 1.0 EU per μg by the LAL method.
- Purity
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
- Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
- Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
- Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
Biotinylated Human EGFRvIII, Avitag,His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
The purity of Biotinylated Human EGFRvIII, Avitag,His Tag (Cat. No. EGR-H82E0) was more than 90% and the molecular weight of this protein is around 60-70 kDa verified by SEC-MALS.
Immobilized Biotinylated Human EGFRvIII, Avitag,His Tag (Cat. No. EGR-H82E0) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate, can bind Anti-EGFRvIII Antibody , Human IgG1 with a linear range of 0.1-3 ng/mL (QC tested).
Immobilized CetuxiMab at 1 μg/mL (100 μL/well) can bind Biotinylated Human EGFRvIII, Avitag,His Tag (Cat. No. EGR-H82E0) with a linear range of 0.2-2 ng/mL (Routinely tested).
- Citations
Small-molecule probes for affinity-guided introduction of biocom-patible handles on metal-binding proteins
Authors: Mortensen MR, et al.
Journal: Bioconjug Chem 2018
Application: SPR
Request for Full-text
- Amino Acid Sequence
LEEKKGNYVVTDHGSCVRACGADSYEMEEDGVRKCKKCEGPCRKVCNGIGIGEFKDSLSINATNIKHFKNCTSISGDLHILPVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPENRTDLHAFENLEIIRGRTKQHGQFSLAVVSLNITSLGLRSLKEISDGDVIISGNKNLCYANTINWKKLFGTSGQKTKIISNRGENSCKATGQVCHALCSPEGCWGPEPRDCVSCRNVSRGRECVDKCNLLEGEPREFVENSECIQCHPECLPQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVMGENNTLVWKYADAGHVCHLCHPNCTYGCTGPGLEGCPTNGPKIPSGLNDIFEAQKIEWHEHHHHHH
- BackgroundThe epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is the cell-surface receptor for members of the epidermal growth factor family (EGF-family) of extracellular protein ligands. The epidermal growth factor receptor is a member of the ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). Mutations affecting EGFR expression or activity could result in cancer.The type III EGF deletion-mutant receptor (EGFRvIII) is the most common mutation and was first identified in primary human glioblastoma tumors; EGFR gene amplification is correlated with the structural rearrangement of the gene. The EGFRvIII gene has an in-frame deletion of 801 base pairs, corresponding to exons 2–7 in the mRNA, resulting in the deletion of amino acids 30-297 in the extracellular domain and the generation of a glycine at the fusion point.
- References
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
酶标仪选择重复性好的，线性范围宽的，故障率底的，售后服务跟的上的厂家的仪器就好了。
想请教一下各位大神，为什么我做的Caco-2细胞的药物干预，用酶标仪检测CCK8,5/6孔总是异常，按理说，药物干预后，数据应该是递增或递减的，然而234孔递减，5/6孔却上升了，7、8孔又是递减。请问有人有遇到过这种情况吗？？在此先谢谢各位亲了~
CSY-E96D动物疾病快速诊断仪采用固相酶联免疫吸附ELISA的原理,即酶联免疫法；可定量快速畜牧类疾病诊断如禽流感、猪瘟、猪蓝耳、伪狂犬等疾病，广泛应用于养殖场、屠宰场、肉产品深加工企业、检验检疫单位使用。
各位前辈，MTT法加样后第一天阳性组镜下看细胞全死了，样品组和阴性组镜下状态还可以，加DMSO后样品孔和阴性孔颜色粉红，阳性孔红紫到发黑，酶标仪检测，样品组和阴性组大概0.2-0.4，阳性组却有1.2-1.4，请问，这是怎么回事？细胞接板密度为4*104,100μL。向各位求助了，万分感谢！
测器和微处理器控制系统等组成.
光源灯发出的光线经过滤光片或单色器后,成为一束单色光.该单色光束经过酶标板中的待测标本,被标本吸收掉一部分后,到达光电检测器.光电检测器将投照到
上面的光信号的强弱转变成电信号的大小.此电信号经前置放大、对数放大、模数转换等处理后,送人微处理器进行数据处理和计算,最后通过显示器和打印机输出
测试结果.
请问BAC蛋白浓度测定波长是562，我们这边酶标仪的滤光片波长最接近的是595，这样也可以测吗
酶标仪有单波长和双波长检测功能有时使用者不知在什么情况下使用单或双波长检测。所谓的“单波长”就是使用一种对显色具最大吸收的波长即450 nm或492 nm进行比色测定；而“双波长”则除了用对显色具最大吸收的波长即450 nm或492 nm进行比色测定外，同时用对特异显色不敏感的波长如630 nm进行测定，酶标仪最后打印出来的吸光度则为二者之差。630 nm波长下得到的吸光度是非特异的，来自于板子上诸如指纹、灰尘、脏物等所致的吸收。因此，在ELISA比色测定中，最好使用双波长，且不必设空白孔。
